Bioactive Natural Products: Facts, Applications, and Challenges

Kourkoutas, Yiannis; Karatzas, Kimon-Andreas; Valdramidis, Vasilis; Chorianopoulos, Nikos

doi:10.1155/2015/684109

Cited by 10 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Naturally occurring molecules are challenging synthetic targets that require groundbreaking synthetic methodologies for the expeditious construction of carbon skeletons with the introduction, organization, and transformation of flexible functional groups. [1][2][3][4][5] Natural products are attractive when they are relatively small molecules and exhibit diverse biological activities, exemplified by their influential function beyond the horizon of drug discovery and drug development. [6][7][8][9][10] Several synthetic intermediates have been reported to synthesize bioactive natural R. Bharath Krishna R. Bharath Krishna was born in 1999 in Kerala, India.…”

Section: Introductionmentioning

confidence: 99%

Arynes as synthetic linchpins towards the construction of diversely functionalized natural product skeletons

2023

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Arynes as synthetic linchpins towards the construction of diversely functionalized natural product skeletons

2023

View full text Add to dashboard Cite

show abstract

“…While the use of bioactive natural products alone or in combination to combat antibacterial resistance is increasingly applied [21][22][23][24][25], several antimicrobial combinations have been studied for synergy in vitro and in vivo against Gram-positive and Gram-negative pathogens [19,[25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40]. However, limited research has been carried out to evaluate the effect of combining antibiotics with L. enzymogenes bioactive metabolites, as a virulence-attenuating combination therapy against resistant strains.…”

Section: Introductionmentioning

confidence: 99%

Antibiotic—Lysobacter enzymogenes proteases combination as a novel virulence attenuating therapy

Suaifan¹,

Rahman²,

Abu-Odeh³

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

Minimizing antibiotic resistance is a key motivation strategy in designing and developing new and combination therapy. In this study, a combination of the antibiotics (cefixime, levofloxacin and gentamicin) with Lysobacter enzymogenes (L. enzymogenes) bioactive proteases present in the cell- free supernatant (CFS) have been investigated against the Gram-positive methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA) and the Gram-negative Escherichia coli (E. coli O157:H7). Results indicated that L. enzymogenes CFS had maximum proteolytic activity after 11 days of incubation and higher growth inhibitory properties against MSSA and MRSA compared to E. coli (O157:H7). The combination of L. enzymogenes CFS with cefixime, gentamicin and levofloxacin at sub-MIC levels, has potentiated their bacterial inhibition capacity. Interestingly, combining cefixime with L. enzymogenes CFS restored its antibacterial activity against MRSA. The MTT assay revealed that L. enzymogenes CFS has no significant reduction in human normal skin fibroblast (CCD-1064SK) cell viability. In conclusion, L. enzymogenes bioactive proteases are natural potentiators for antimicrobials with different bacterial targets including cefixime, gentamicin and levofloxacin representing the beginning of a modern and efficient era in the battle against multidrug-resistant pathogens.

show abstract

“…Natural products from herb or food have attracted people’s attention due to their wide bioactivities and low toxic and side effects, and have been used in functional additives ( Kourkoutas et al, 2015 ). Astragalus polysaccharides (APS) is the primary bioactive ingredient isolated from Astragalus membranaceus , a representative Traditional Chinese medicine.…”

Section: Introductionmentioning

confidence: 99%

Astragalus polysaccharides alleviates lipopolysaccharides-induced inflammatory lung injury by altering intestinal microbiota in mice

Ming

Zhuang

et al. 2022

Front. Microbiol.

View full text Add to dashboard Cite

Inflammatory lung injury is a common respiratory disease with limited therapeutic effects. Increasing opinions approved that prevention is more important than drug treatment for inflammatory lung injury. Astragalus polysaccharides (APS) has multiple bioactivities including anti-inflammation and immunoregulation. However, its preventive effects on inflammatory lung injury remain unclear. In this study, mice were pretreated with APS via intragastric gavage and then were intratracheally instilled with lipopolysaccharides (LPS) to determine the role of APS in preventing lung injury. The results showed that APS pre-treatment improved the pathological changes of lung tissues, reduced the neutrophils infiltration, and inhibited the LPS-induced inflammation. Increasing evidence confirmed the close relationship between intestinal microbiota and lung inflammatory response. 16S rRNA analysis showed that APS treatment changed the microbiota composition in colon, increased the abundance of short-chain fatty acids (SCFAs)-producing genus such as Oscillospira, Akkermansia, and Coprococcus. Also, APS treatment significantly increased the serum concentrations of SCFAs including butyrate and propionate, and their anti-inflammation effects were demonstrated on mice primary alveolar macrophages. Our data confirmed the preventive effects of APS on LPS-induced lung injury, which were partly contributed by the alteration of intestinal microbiota composition and the resulting increase of serum SCFAs.

show abstract

Bioactive Natural Products: Facts, Applications, and Challenges

Cited by 10 publications

References 9 publications

Arynes as synthetic linchpins towards the construction of diversely functionalized natural product skeletons

Arynes as synthetic linchpins towards the construction of diversely functionalized natural product skeletons

Antibiotic—Lysobacter enzymogenes proteases combination as a novel virulence attenuating therapy

Astragalus polysaccharides alleviates lipopolysaccharides-induced inflammatory lung injury by altering intestinal microbiota in mice

Contact Info

Product

Resources

About